Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
The American College of Rheumatology (ACR) and the American College of Hip Surgery (AAHKS) have released new guidelines.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
More People Than Previously Believed Have Schizophrenia.
2.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
3.
Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.
4.
Including Bereavement in the Care Continuum.
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Exploring the Potential of Bendamustine in Cancer Treatment
3.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
4.
Neutrophil Profiling and AI Rewrites Cancer Diagnosis
5.
Everything You Need to Know About CA 19-9 and Cancer Diagnosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge